Catalyst Rich 12 Months Ahead for U.S. Biopharma Co.
Source: Scott Henry  (8/29/23)
Investors can expect to see new drug application filings, a PDUFA meeting outcome, clinical trial results and revenue stream additions, noted a ROTH Capital Partners report. More >

DNA Tech Co. Launches MRNA Platform and Files Two Patents
Source: Streetwise Reports  (8/29/23)
This company has announced the general availability of its Linea IVT platform evaluation kits and the first kit shipment to an existing Linea IVT Template customer. It has also filed two provisional patent applications for its technologies to reduce the impurities and decrease manufacturing costs for mRNA therapies like some COVID-19 vaccines. Read to see what experts are saying about the stock. More >

FDA Approves New Oncology Drug for Clinical Trials
Source: Dr. Robert Driscoll  (8/28/23)
The first in-human trial of this investigative small molecule is expected to start in Q4/23, noted a Wedbush report. More >

The Bond Market Has the Blues, Oil Breaks to the Upside and Moderna to the Downside
Source: Ron Struthers  (8/7/23)
The long end of the bond market is starting to price in sticky inflation, and Ron Struthers of Struthers' Stock Reports expects interest rates to rise further. Higher energy prices will start adding to inflation again, adding to the problem. Moderna has broken down on the chart and will be reporting red ink in the next few years. Time to go short. More >

Biotech Co. An Attractive Investment
Source: Clive Maund  (8/4/23)
Technical Analyst Clive Maund reviews Awakn Life Sciences Corp.'s 26-month and year-to-date charts to tell you why he believes it is an attractive investment. More >

Second Half of 2023 Is Catalyst Rich for This Biopharma Co.
Source: Patrick Trucchio  (7/19/23)
The firm continues advancing its lead drug candidates, including those for anxiety and treatment-resistant depression, noted an H.C. Wainwright & Co. report. More >

Approval Sought in Japan for New SARS-CoV-2 Vaccine
Source: Ed Arce  (7/7/23)
The vaccine developer's partner in Japan is already working on getting a manufacturing facility built there, noted an H.C. Wainwright & Co. report. More >

Co. Addresses Opioid Crisis Through Novel Platforms
Source: Boobalan Pachaiyappan  (7/7/23)
This California biotech, developing products that prevent opioid abuse and overdose, gained coverage by an H.C. Wainwright & Co. analyst, an initiation report noted. More >

New Psoriasis Drug Shown More Effective Than On-Market One
Source: Julian Harrison   (7/6/23)
Recent clinical trial results show the oral interleukin-23 receptor to be a "cleaner" target than non-receptor tyrosine kinase 2, noted a BTIG report. More >

Co. With Alzheimer's App 'Meaningfully Undervalued,' Analyst Says
Source: Stefan Quenneville  (7/5/23)
Despite having revenues below expectations, one analyst says this health company's Alzheimer's dementia diagnosis app is gaining commercial traction. More >

Biotech Co. Remains Opportunity for Those With High Risk Tolerance
Source: Stefan Quenneville  (6/30/23)
Recently, Antibe Therapeutics released its fiscal 2023 year-end (FQ423) results, which remained inline with expectations, noted an Echelon Capital research note. More >

Q3: Chen Is Still Bullish on This Precious Metal
Source: Streetwise Reports  (6/29/23)
Asset manager Chen Lin continues to rely heavily on this precious metal. Find out his top picks for the third quarter of 2023. More >

New Drug for Bone Growth Disorder Improves Height Velocity
Source: Dr. Thomas Shrader  (6/21/23)
Phase 2 trial data at six months are positive in children with achondroplasia, noted a BTIG report. More >

Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries
Source: Streetwise Reports  (6/16/23)
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream. More >

777% Gain Implied in Analyst's Target Price on Biopharma Co.
Source: Dr. Yi Chen  (6/14/23)
Results from a Phase 2 trial of this U.S. company's cystic fibrosis drug are due out next month, noted an H.C. Wainwright & Co. report. More >

Biotech Co. To Exit Health Care Services
Source: Streetwise Reports  (6/12/23)
Friday, Awakn Life Sciences Corp. announced it would be taking focus away from healthcare services and instead concentrate its efforts exclusively on research and development for therapeutics for addiction treatment. Read more to learn what the global addiction treatment market looks like and where the company is headed in the future. More >

Key Catalyst for US Biopharma Stock on Track for Q4/23
Source: Ed Arce  (6/9/23)
Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report. More >

FDA Approval, Private Placement Funding Buoy Biotech Firm
Source: Streetwise Reports  (6/5/23)
Krystal Biotech Inc. appears to be picking up steam for the year's second half. The company's Vyjuvek topical gel for treating Dystrophic Epidermolysis Bullosa (DEB) was approved by the FDA on May 19, leading to a major funding announcement. More >

Analyst Says Pharma Co. 'Meaningfully Undervalued'
Source: Stefan Quennevill  (6/1/23)
"We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note. More >

Animal Feed Company Evaluating Strategic Alternatives
Source: Streetwise Reports  (5/23/23)
Avivagen is considering strategic plans to maximize value to shareholders. Read more to see what the possibilities may be for shareholder profit. More >

Biopharma Co. Ceases Program to Optimize Resources
Source: Hartaj Singh  (5/16/23)
This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report. More >

Pharmaceutical Company Sets Gold Standard for New Drugs
Source: Streetwise Reports  (4/26/23)
Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history. More >

As Countries Bolster Defense, Opportunities Emerge
Source: Streetwise Reports  (4/21/23)
Defense stocks are uniquely positioned to enjoy considerable, reliable funding from government contracts. This stability, and the ensuing profitability, increases during times of international political instability. More >

Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial
Source: Streetwise Reports  (4/19/23)
Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill. More >

Oncology Co. Receives Buy Rating for New Drug Trials
Source: Dr. Joseph Pantginis  (4/18/23)
A California drug company is moving into new phases of drug trials targeted at solid tumors, noted an H.C.Wainwright & Co. report. More >